Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 12, 2012, Pages 1289-1294

  Paludetto, Marie Noelle ^a   Olivier Abbal, Pascale ^a,b   Montastruc, Jean Louis ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b Faculté de Médecine Centre Hospitalo universitaire   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Adverse drug reaction; Drug withdrawal; Pharmacoepidemiology; Pharmacovigilance

Indexed keywords

ALMITRINE; BENFLUOREX; BUFEXAMAC; CLORAZEPATE; KETOCONAZOLE; PIOGLITAZONE; ROSIGLITAZONE; VERALIPRIDE;

ANIMAL EXPERIMENT; ARTICLE; CASE CONTROL STUDY; CASE STUDY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FRANCE; INFORMATION PROCESSING; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; FRANCE; HUMANS; PHARMACOVIGILANCE; TIME FACTORS;

EID: 84870699940     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3333     Document Type: Article

References (11)

1. Olivier P, Montastruc JL. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf 2006; 15: 808-812.
2. http://www.afssaps.fr/.
3. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In Textbook of adverse drug reactions, Davies DM (ed.). Oxford University Press: Oxford, 1985; 12-38.
4. Anatomical therapeutic chemical (ATC) classification index. WHO Collaborating Center for Drug Statistics Methodology: Geneva, 1992.
5. Clarke A, Deeks JJ, Shakir SAW. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006; 29: 175-181.
6. Arnaiz JA, Carne X, Riba N, et al. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol 2001; 57: 89-91.
7. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Safety-related regulatory actions for biological approved in the United States and the European Union. JAMA 2008; 300: 1887-1896.
8. DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities (1.5.2001). L 121:34-44.
9. Mol PGM, Straus SMJM, Piening S, et al. A decade of safety-related regulatory action in the Netherlands. Drug Saf 2010; 33: 463-474.
10. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ 2005; 172: 765-767.
11. Thiessard F, Roux E, Miremont-Salamé G, et al. Trends in Spontaneous Adverse Drug Reaction Reports to the French Pharmacovigilance System (1986-2001). Drug Saf 2005; 28: 731-740.